The diverse and complex roles of radiation on cancer treatment: therapeutic target and genome maintenance
- PMID: 22860229
- PMCID: PMC3410581
The diverse and complex roles of radiation on cancer treatment: therapeutic target and genome maintenance
Abstract
Cancer is a genetic disease, grows exponentially with the development of intrinsic and acquired treatment resistance. Past decade has witnessed a considerable progress towards the treatment and understanding of proposed hallmarks of cancer and together with advances in early detection and various treatment modalities. Radiation therapy is an integral part of cancer treatment armamentarium. In developed countries more than half of all cancer patients receive radiation therapy during their course of illness. Although radiation damages both cancer and normal cells, the goal of radiation therapy is to maximize the radiation dose to abnormal cancer cells while minimizing exposure to normal cells, which is adjacent to cancer cells or in the path of radiation. In recent years, life expectancy increases among cancer patients and this increase is due to the results of early diagnosis, screening efforts, improved treatments and with less late effects mostly secondary cancer development. Therefore, cancer survivorship issues have been gaining prominence in the area of radiation oncology research. Understanding the tradeoff between the expected decreases in normal tissue toxicity resulting from an improved radiation dose distribution to the targeted site is an increasingly pertinent, yet needed attention and research in the area of radiation oncology. In recent years, a number of potential molecular targets that involve either with radiation increased tumor cell killing or protecting normal cells have been identified. For clinical benefits, translating these findings to maximize the toxicity of radiation on tumor cells while safeguarding early or late normal cell toxicities using molecular targeted radioprotectors will be useful in radiation treatment.
Keywords: Cancer; normal genome maintenance; radiation therapy; radioprotectors.
Figures


Similar articles
-
Biological response of cancer cells to radiation treatment.Front Mol Biosci. 2014 Nov 17;1:24. doi: 10.3389/fmolb.2014.00024. eCollection 2014. Front Mol Biosci. 2014. PMID: 25988165 Free PMC article. Review.
-
The CD73/Ado System-A New Player in RT Induced Adverse Late Effects.Cancers (Basel). 2019 Oct 16;11(10):1578. doi: 10.3390/cancers11101578. Cancers (Basel). 2019. PMID: 31623231 Free PMC article. Review.
-
Natural Radioprotectors on Current and Future Perspectives: A Mini-Review.J Pharm Bioallied Sci. 2022 Apr-Jun;14(2):57-71. doi: 10.4103/jpbs.jpbs_502_21. Epub 2022 Jul 18. J Pharm Bioallied Sci. 2022. PMID: 36034486 Free PMC article. Review.
-
Overview of resistance to systemic therapy in patients with breast cancer.Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1. Adv Exp Med Biol. 2007. PMID: 17993229 Review.
-
Beware the Medical-Industrial Complex.Oncologist. 1996;1(4):IV-V. Oncologist. 1996. PMID: 10388005
Cited by
-
Applications and perspectives of tumor organoids in radiobiology (Review).Oncol Rep. 2024 Aug;52(2):100. doi: 10.3892/or.2024.8759. Epub 2024 Jun 21. Oncol Rep. 2024. PMID: 38904192 Free PMC article. Review.
-
Impact of Induced Syncytia Formation on the Oncolytic Potential of Myxoma Virus.Oncolytic Virother. 2019 Dec 9;8:57-69. doi: 10.2147/OV.S220420. eCollection 2019. Oncolytic Virother. 2019. PMID: 31850282 Free PMC article.
-
TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation.BMC Immunol. 2024 Jul 25;25(1):48. doi: 10.1186/s12865-024-00643-x. BMC Immunol. 2024. PMID: 39054418 Free PMC article.
-
Prognostic significance of AKR1C4 and the advantage of combining EBV DNA to stratify patients at high risk of locoregional recurrence of nasopharyngeal carcinoma.BMC Cancer. 2022 Aug 11;22(1):880. doi: 10.1186/s12885-022-09924-3. BMC Cancer. 2022. PMID: 35953777 Free PMC article.
-
Cancer Nanopharmaceuticals: Physicochemical Characterization and In Vitro/In Vivo Applications.Cancers (Basel). 2021 Apr 15;13(8):1896. doi: 10.3390/cancers13081896. Cancers (Basel). 2021. PMID: 33920840 Free PMC article. Review.
References
-
- Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893–1907. - PubMed
-
- Weckermann D, Müller P, Wawroschek F, Harzmann R, Riethmüller G, Schlimok G. Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. J Urol. 2001;166:699–703. - PubMed
-
- Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst. 1999;91:80–85. - PubMed
-
- Pfitzenmaier J, Ellis WJ, Arfman EW, Hawley S, McLaughlin PO, Lange PH, Vessella RL. Telomerase activity in disseminated prostate cancer cells. BJU Int. 2006;97:1309–1313. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous